QSAR studies of the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by multiple linear regression (MLR) and support vector machine (SVM)

被引:17
|
作者
Qin, Zijian [1 ]
Wang, Maolin [1 ]
Yan, Aixia [1 ]
机构
[1] Beijing Univ Chem Technol, Dept Pharmaceut Engn, State Key Lab Chem Resource Engn, POB 53,15 BeiSanHuan East Rd, Beijing 100029, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatitis C virus (HCV) NS3/4A protease inhibitors; Quantitative structure-activity relationship (QSAR); Kohonen's self-organizing map (SOM); Multiple linear regression (MLR); Support vector machine (SVM); Sub-dataset analysis; PEPTIDE-BASED INHIBITORS; ALPHA-KETOAMIDES; SERINE-PROTEASE; ANTIVIRAL ACTIVITY; POTENT INHIBITORS; CRYSTAL-STRUCTURE; DISCOVERY; DESIGN; PROTEINASE; BINDING;
D O I
10.1016/j.bmcl.2017.05.001
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In this study, quantitative structure-activity relationship (QSAR) models using various descriptor sets and training/test set selection methods were explored to predict the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by using a multiple linear regression (MLR) and a support vector machine (SVM) method. 512 HCV NS3/4A protease inhibitors and their IC50 values which were determined by the same FRET assay were collected from the reported literature to build a dataset. All the inhibitors were represented with selected nine global and 12 2D property-weighted autocorrelation descriptors calculated from the program CORINA Symphony. The dataset was divided into a training set and a test set by a random and a Kohonen's self-organizing map (SOM) method. The correlation coefficients (r(2)) of training sets and test sets were 0.75 and 0.72 for the best MLR model, 0.87 and 0.85 for the best SVM model, respectively. In addition, a series of sub-dataset models were also developed. The performances of all the best sub-dataset models were better than those of the whole dataset models. We believe that the combination of the best sub-and whole dataset SVM models can be used as reliable lead designing tools for new NS3/4A protease inhibitors scaffolds in a drug discovery pipeline. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2931 / 2938
页数:8
相关论文
共 50 条
  • [41] Avoiding drug resistance against HCV NS3/4A protease inhibitors
    Romano, K.
    Ali, A.
    Schiffer, C.
    ANTIVIRAL THERAPY, 2010, 15 : A25 - A25
  • [42] TMC-435350 HCV NS3/4A Protease Inhibitor Anti-Hepatitis C Virus Drug
    Davies, S.
    DRUGS OF THE FUTURE, 2009, 34 (07) : 545 - 553
  • [43] Potent novel inhibitors against hepatitis C virus NS3 (HCV NS3 GT-3a) protease domain
    Ikram, Saima
    Ahmad, Jamshaid
    Rehman, Irshad-Ur
    Durdagi, Serdar
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2020, 101
  • [44] A hepatitis C virus (HCV) NS3/4A protease-dependent strategy for the identification and purification of HCV-infected cells
    Breiman, Adrien
    Vitour, Damien
    Vilasco, Myriam
    Ottone, Catherine
    Molina, Sonia
    Pichard, Lydiane
    Fournier, Chantal
    Delgrange, David
    Charneau, Pierre
    Duverlie, Gilles
    Wychowski, Czeslaw
    Maurel, Patrick
    Meurs, Eliane F.
    JOURNAL OF GENERAL VIROLOGY, 2006, 87 : 3587 - 3598
  • [45] A MOUSE MODEL WITH LONG TERM EXPRESSION OF HEPATITIS C VIRUS NS3/4A PROTEASE FOR THE PHARMACOKINETIC AND PHARMACODYNAMIC (PK/PD) STUDY OF HCV PROTEASE INHIBITORS
    Lin, J.
    Hong, J.
    Lim, S.
    Qin, X.
    Pan, L.
    Huang, L.
    Liu, J.
    Schaefer, C.
    Ammons, S.
    Seiwert, S.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S131 - S132
  • [46] SAR and pharmacokinetic studies on phenethylamide inhibitors of the hepatitis C virus NS3/NS4A serine protease
    Malancona, S
    Colarusso, S
    Ontoria, JM
    Marchetti, A
    Poma, M
    Stansfield, I
    Laufer, R
    Di Marco, A
    Taliani, M
    Verdirame, M
    Gonzalez-Paz, O
    Matassa, VG
    Narjes, F
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (17) : 4575 - 4579
  • [47] Progress toward the synthesis of a novel series of hepatitis C NS3/4A protease inhibitors
    Lodhia, Nayna A.
    Carrico-Moniz, Dora
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237
  • [48] Allosteric Inhibitors of the NS3 Protease from the Hepatitis C Virus
    Abian, Olga
    Vega, Sonia
    Sancho, Javier
    Velazquez-Campoy, Adrian
    PLOS ONE, 2013, 8 (07):
  • [49] Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease
    Zhang, RM
    Durkin, JP
    Windsor, WT
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (07) : 1005 - 1008
  • [50] Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates
    Lopez-Labrador, F. Xavier
    Moya, Andres
    Gonzalez-Candelas, Fernando
    ANTIVIRAL THERAPY, 2008, 13 (04) : 481 - 494